Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job

Workshop

[In-Person] Antibody-Drug Conjugates from Discovery to Development: Chemistry, Engineering, Characterization, CMC, PK/Tox, Clinical design and Intellectual Property


Speakers: Mohan Srinivasan (Loxo/Lilly), Thomas Pillow (Genentech), Bernhard Geierstanger (Firefly Biologics), Laurence Fayadat-Dilman (Merck), Travis Biechele (Shasqi), Judy Hsii (SutroBio), Hui Zhao (Exelixis), Sara Glickstein Bar-Zeev (Genentech), Maya Skubatch (Wilson Sonsini)
Organizers: Mohan Srinivasan (Loxo Oncology at Lilly), Thomas Pillow (Genentech), Laurence Fayadat-Dilman (Merck)
Date: 2024-03-28
Time: 8:45-17:30 Pacific Time
Registration fee: Regular attendees: $295; Academic/Students/Postdocs: $45; Out-of-Pocket: $45; Major Sponsorship: $3000; Vendor Show: $695, Happy Hour Sponsorship: $975; Lunch Sponsorship: $1250; On-site Registration: $500
Location: Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor: (2)Alturas Analytics; Resolian
Vendor show vendors registered to date: (28)Abzena; Altruist Biologics; AsymBio; Aton Biotech; BioAgilytix; Biocytogen Boston Corp; BioIVT; Biomere; BioTether Sciences; Celerion; Cellentia Inc.; ChemPartner Shanghai; Correlia Biosystems Inc; Curia; Discovery Life Sciences; Emery Pharma; Gator Bio; JOINN Biologics Us Inc.; KACTUS; KCAS Bio; Lonza; Meadowhawk Biolabs; Milliporesigma; Mycenax; Nanotemper; newcells biotech; PharmaBlock; Pharmalegacy
Registration: http://www.PBSS.org
Registration deadline:2024-03-27  (it will close sooner if the seating cap is reached)

About the Topic

Sponsored by Resolian, Alturas Analytics, Mycenax

 
Topics:

  • ADC overview
  • Target selection
  • Chemistry of linker payload & conjugation techniques
  • Antibody Engineering for ADCs
  • Analytical and Biophysical Characterization of ADCs
  • In-vitro and in-vivo activity considerations for ADCs
  • CMC Challenges and Opportunities in ADCs
  • PK and Toxicology Study Designs
  • Clinical Trial Design for ADCs
  • Intellectual Property of ADCs
Time (PST) Topic Speaker
8:45 am - 8:55 am PBSS Welcome Remarks Shichang Miao, PhD, PBSS
8:55 am - 9:15 am Workshop Overview and ADC overview Mohan Srinivasan, PhD, Associate VP, Biologics, Loxo/Lilly
9:15 - 9:35 am ADC Target Characterization and Selection Strategies Travis Biechele, PhD, VP of Research at Shasqi
9:35 am - 10:20 am Chemistry of Linker Payload & Conjugation Techniques Thomas Pillow, PhD, Distinguished Scientist, Genentech
10:20 am - 11:05 am Antibody Engineering for ADCs Bernhard Geierstanger, PhD, Co-Founder and CTO, Firefly Biologics 
11:05 am - 11:15 am Major Sponsor Presentation Resolian 
11:15 am - 11:35 am Break and Vendor Show  -
11:35 am - 12:20 pm Analytical and Biophysical Characterization of ADCs Laurence Fayadat-Dilman, PhD, Executive Director, Discovery Biologics, Merck
12:20 pm - 1:10 pm Lunch Break Sponsor (Mycenax)
1:10 pm - 1:40 pm In-vitro and In-vivo Pharmacology for ADCs Travis Biechele, PhD, Senior Principal Scientist, Merck 
1:40 pm - 2:25 pm CMC Challenges and Opportunities in ADCs Judy Hsii, MS, Executive Director, Sutro Biopharma 
2:25 pm - 3:10 pm PK and Toxicology Study Designs Hui Zhao, PhD, Senior Director of Translational Biology, Exelixis 
3:10 pm - 3:20 pm Major Sponsor Presentation Alturas Analytics
3:20 pm - 3:40 pm Break and Vendor Show  -
3:40 pm - 4:20 pm Clinical Trial Design for ADCs Sara Glickstein Bar-Zeev, PhD, Principal Clinical Scientist, Genentech
4:20 pm - 5:00 pm Intellectual Property of ADCs Maya Skubatch, JD, Partner at Wilson Sonsini Goodrich & Rosati 
5:00 pm - 5:30 pm Panel Discussion & Closing Remarks All Speakers
5:30 PM - 6:30 pm Happy Hour Sponsor (Correlia Biosystems)

 


2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
┬ęPharmaceutical & BioScience Society, International; Last Modified: 4/23/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Hypha Discovery Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Lena Biosciences Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
Submit a Text Ad